Do you recommend 3 months of chemotherapy, 6 months of chemotherapy, or no chemotherapy along atezolizumab in patients with low risk (T1-3, N1) Stage III dMMR colon cancer?
In the ATOMIC trial evaluating the addition of adjuvant atezolizumab in this setting, patients received 6 months of chemotherapy plus 12 months of total atezolizumab. However, given the IDEA data, would you consider 3 months of chemotherapy to be adequate in this population? Given the data from metastatic disease, is chemotherapy needed in this setting?
Community PollStarted
What adjuvant chemotherapy, if any, do you give along atezolizumab for patients with dMMR Stage III colon cancer?
47 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Medical Oncology · Montefiore Einstein Comprehensive Cancer Center
Answered on
This is a good question (and a data-free zone). pMMR low-risk stage III disease can be treated with 3 months of CAPOX or 6 months of FOLFOX, based on the IDEA trial. The residual risk of relapse for this entity, after chemotherapy, is ~20%. FOLFOX for 3 months was inferior to 6 months by a few perce...
Join for free or sign in to see the full answer